{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:03:06Z","timestamp":1774526586806,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","award":["2021\/ATRG2028"],"award-info":[{"award-number":["2021\/ATRG2028"]}],"id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"DOI":"10.1186\/s12962-026-00727-y","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T11:47:39Z","timestamp":1771501659000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Economic evaluations of the primary prevention programs for viral hepatitis-related liver disease and liver cancer: a systematic literature review"],"prefix":"10.1186","volume":"24","author":[{"given":"Milena","family":"Lewandowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenghan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalini","family":"Wijekulasuriya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Putu Novi Arfirsta","family":"Dharmayani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Carrigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Goodall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose","family":"Boutros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amany","family":"Zekry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Zurynski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"issue":"2","key":"727_CR1","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3350\/cmh.2023.0092","volume":"29","author":"P Konyn","year":"2023","unstructured":"Konyn P, Ahmed A, Kim D. The current trends in the health burden of primary liver cancer across the Globe. Clin Mol Hepatol. 2023;29(2):358\u201362.","journal-title":"Clin Mol Hepatol"},{"issue":"10","key":"727_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589\u2013604.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"727_CR3","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.jhep.2009.02.005","volume":"50","author":"M Sherman","year":"2009","unstructured":"Sherman M. Prevention of hepatocellular carcinoma: the holy Grail of hepatitis B treatment. J Hepatol. 2009;50(5):854\u20136.","journal-title":"J Hepatol"},{"issue":"2","key":"727_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jhep.2015.04.026","volume":"63","author":"S Sharma","year":"2015","unstructured":"Sharma S, Carballo M, Feld JJ, Janssen HLA. Immigration and viral hepatitis. J Hepatol. 2015;63(2):515\u201322.","journal-title":"J Hepatol"},{"issue":"5","key":"727_CR5","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/1753-6405.12826","volume":"42","author":"JH MacLachlan","year":"2018","unstructured":"MacLachlan JH, Cowie BC. Cultural and linguistic diversity of people living with chronic hepatitis B in 2011\u20132016: changing migration, shifting epidemiology. Aust N Z J Public Health. 2018;42(5):441\u20133.","journal-title":"Aust N Z J Public Health"},{"key":"727_CR6","doi-asserted-by":"crossref","unstructured":"Brunner N, Bruggmann P. Trends of the global hepatitis C disease burden: strategies to achieve elimination. J Prev Med Public Health. 2021;54(4):251\u20138.","DOI":"10.3961\/jpmph.21.151"},{"key":"727_CR7","unstructured":"ASHM Health. ASHM Health. [cited 2024 Oct 26]. Viral Hepatitis Mapping Project: National Reports. Available from: https:\/\/ashm.org.au\/resources\/viral-hepatitis-mapping-project\/."},{"issue":"4","key":"727_CR8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","volume":"45","author":"JF Perz","year":"2006","unstructured":"Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529\u201338.","journal-title":"J Hepatol"},{"issue":"4","key":"727_CR9","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1053\/j.gastro.2010.12.032","volume":"140","author":"F Kanwal","year":"2011","unstructured":"Kanwal F, Hoang T, Kramer JR, Asch SM, Goetz MB, Zeringue A, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011;140(4):1182\u2013e11881.","journal-title":"Gastroenterology"},{"issue":"2","key":"727_CR10","doi-asserted-by":"publisher","first-page":"taz007","DOI":"10.1093\/jtm\/taz007","volume":"26","author":"C Greenaway","year":"2019","unstructured":"Greenaway C, Castelli F. Infectious diseases at different stages of migration: an expert review. J Travel Med. 2019;26(2):taz007.","journal-title":"J Travel Med"},{"issue":"Suppl 1","key":"727_CR11","first-page":"115","volume":"38","author":"M Subic","year":"2018","unstructured":"Subic M, Zoulim F. How to improve access to therapy in hepatitis B patients. Liver Int Off J Int Assoc Study Liver. 2018;38(Suppl 1):115\u201321.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"issue":"5","key":"727_CR12","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1097\/HEP.0000000000000459","volume":"78","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Tran A, Yeh ML, Yasuda S, Tsai PC, Huang CF, et al. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase. Hepatology. 2023;78(5):1558.","journal-title":"Hepatology"},{"key":"727_CR13","unstructured":"Ihtiram Hussain. Direct-Acting Antiviral Therapy in the Treatment of Chronic Hepatitis C: A Systematic Review and Meta-Analysis of Sustained Virologic Response (SVR) and Long-Term Outcomes. Biores Sci [Internet]. 2025 [cited 2026 Jan 14]; Available from: https:\/\/bioresscientia.com\/article\/direct-acting-antiviral-therapy-in-the-treatment-of-chronic-hepatitis-c-a-systematic-review-and-meta-analysis-of-sustained-virologic-response-svr-and-long-term-outcomes."},{"issue":"12","key":"727_CR14","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.jval.2020.06.015","volume":"23","author":"D Tordrup","year":"2020","unstructured":"Tordrup D, Hutin Y, Stenberg K, Lauer JA, Hutton DW, Toy M, et al. Cost-Effectiveness of testing and treatment for hepatitis B virus and hepatitis C virus infections: an analysis by Scenarios, Regions, and income. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2020;23(12):1552\u201360.","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"issue":"1","key":"727_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12916-021-02204-0","volume":"20","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med. 2022;20(1):23.","journal-title":"BMC Med"},{"key":"727_CR16","unstructured":"The NHS Economic Evaluation Database (NHS EED). [Internet]. [cited 2025 Mar 8]. Available from: https:\/\/www.crd.york.ac.uk\/CRDWeb\/ShowRecord.asp?ID=32002000739."},{"key":"727_CR17","doi-asserted-by":"crossref","unstructured":"Tian FF, Farinaz; Feng Z, Biondi MJ, Mendlowitz AB, Feld, Jordan J, Sander. Beate. Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries. 2024;80(2):440\u201350.","DOI":"10.1097\/HEP.0000000000000779"},{"key":"727_CR18","doi-asserted-by":"crossref","unstructured":"Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess [Internet]. 2004 Sep [cited 2025 Apr 22];8(36). Available from: https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta8360\/.","DOI":"10.3310\/hta8360"},{"issue":"5","key":"727_CR19","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.4161\/hv.23827","volume":"9","author":"S Boccalini","year":"2013","unstructured":"Boccalini S, Taddei C, Ceccherini V, Bechini A, Levi M, Bartolozzi D, et al. Economic analysis of the first 20 years of universal hepatitis B vaccination program in italy: an a posteriori evaluation and forecast of future benefits. Hum Vaccines Immunother. 2013;9(5):1119\u201328.","journal-title":"Hum Vaccines Immunother"},{"key":"727_CR20","unstructured":"Ruggeri G. Economic Assessment of an anti-HCV screening program in Italy - ScienceDirect [Internet]. [cited 2024 Oct 21]. Available from: https:\/\/www-sciencedirect-com.ezproxy.lib.uts.edu.au\/science\/article\/pii\/S1098301513019037."},{"issue":"8","key":"727_CR21","doi-asserted-by":"publisher","first-page":"e70319","DOI":"10.1371\/journal.pone.0070319","volume":"8","author":"AT Urbanus","year":"2013","unstructured":"Urbanus AT, Van Keep M, Matser AA, Rozenbaum MH, Weegink CJ, Van Den Hoek A, et al. Is adding HCV screening to the antenatal National screening program in Amsterdam, the Netherlands, Cost-Effective? Jhaveri R, editor. PLoS ONE. 2013;8(8):e70319.","journal-title":"PLoS ONE"},{"issue":"9","key":"727_CR22","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/jvh.12190","volume":"21","author":"AH Miners","year":"2014","unstructured":"Miners AH, Martin NK, Ghosh A, Hickman M, Vickerman P. Assessing the cost-effectiveness of finding cases of hepatitis C infection in UK migrant populations and the value of further research. J Viral Hepat. 2014;21(9):616\u201323.","journal-title":"J Viral Hepat"},{"issue":"10","key":"727_CR23","doi-asserted-by":"publisher","first-page":"e78548","DOI":"10.1371\/journal.pone.0078548","volume":"8","author":"C Rossi","year":"2013","unstructured":"Rossi C, Schwartzman K, Oxlade O, Klein MB, Greenaway C. Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: A Cost-Effectiveness analysis. PLoS ONE. 2013;8(10):e78548.","journal-title":"PLoS ONE"},{"issue":"8","key":"727_CR24","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/j.1478-3231.2011.02559.x","volume":"31","author":"WWL Wong","year":"2011","unstructured":"Wong WWL, Woo G, Jenny Heathcote E, Krahn M. Cost effectiveness of screening immigrants for hepatitis B. Liver Int. 2011;31(8):1179\u201390.","journal-title":"Liver Int"},{"issue":"3","key":"727_CR25","doi-asserted-by":"publisher","first-page":"E662","DOI":"10.9778\/cmajo.20170048","volume":"5","author":"WWL Wong","year":"2017","unstructured":"Wong WWL, Erman A, Feld JJ, Krahn M. Model-based projection of health and economic effects of screening for hepatitis C in Canada. CMAJ Open. 2017;5(3):E662\u201372.","journal-title":"CMAJ Open"},{"issue":"1","key":"727_CR26","doi-asserted-by":"publisher","first-page":"13484","DOI":"10.1038\/s41598-023-39521-8","volume":"13","author":"WWL Wong","year":"2023","unstructured":"Wong WWL, Haines A, Wong J, Hamadeh A, Krahn MD. A province-by-province cost-effectiveness analysis and budget impact analysis of one-time birth cohort screening of hepatitis C virus (HCV) infection in Canada. Sci Rep. 2023;13(1):13484.","journal-title":"Sci Rep"},{"issue":"3","key":"727_CR27","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/AOG.0000000000004652","volume":"139","author":"M Prabhu","year":"2022","unstructured":"Prabhu M, Susich MK, Packer CH, Hersch AR, Riley LE, Caughey AB. Universal hepatitis B antibody screening and vaccination in pregnancy: A Cost-Effectiveness analysis. Obstet Gynecol. 2022;139(3):357.","journal-title":"Obstet Gynecol"},{"key":"727_CR28","unstructured":"Susich M. A cost-effectiveness analysis of universal hepatitis C screening in all United States pregnancies. J Matern Fetal Neonatal Med [Internet]. 2022 [cited 2024 Apr 11]. Available from: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14767058.2021.1949442."},{"issue":"3","key":"727_CR29","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1093\/cid\/cix798","volume":"66","author":"SA Assoumou","year":"2018","unstructured":"Assoumou SA, Tasillo A, Leff JA, Schackman BR, Drainoni ML, Horsburgh CR, et al. Cost-Effectiveness of One-Time hepatitis C screening strategies among adolescents and young adults in primary care settings. Clin Infect Dis Off Publ Infect Dis Soc Am. 2018;66(3):376\u201384.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"727_CR30","doi-asserted-by":"crossref","unstructured":"Younossi Z, Blissett D, Blissett R, Henry L, Younossi Y, Beckerman R, Hunt S. In an era of highly effective treatment, hepatitis C screening of the United States general population should be considered. Liver Int. 2018;38(2):258\u201365 [Internet]. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.13519.","DOI":"10.1111\/liv.13519"},{"key":"727_CR31","unstructured":"Toy M. Cost-Effectiveness of 1-Time Universal Screening for Chronic Hepatitis B Infection in Adults in the United States - PubMed [Internet]. 2022 [cited 2024 Apr 11]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33956937\/."},{"issue":"4","key":"727_CR32","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/cid\/ciy098","volume":"67","author":"JA Barocas","year":"2018","unstructured":"Barocas JA, Tasillo A, Eftekhari Yazdi G, Wang J, Vellozzi C, Hariri S, et al. Population-level outcomes and Cost-Effectiveness of expanding the recommendation for Age-based hepatitis C testing in the united States. Clin Infect Dis Off Publ Infect Dis Soc Am. 2018;67(4):549\u201356.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"5","key":"727_CR33","first-page":"930","volume":"17","author":"MH Eckman","year":"2019","unstructured":"Eckman MH, Ward JW, Sherman KE. Cost effectiveness of universal screening for hepatitis C virus infection in the era of Direct-Acting, pangenotypic treatment regimens. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2019;17(5):930\u2013e9399.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"1","key":"727_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.amepre.2022.08.016","volume":"64","author":"X Jiang","year":"2023","unstructured":"Jiang X, Diaby V, Vouri SM, Lo-Ciganic W, Parker RL, Wang W, et al. Economic impact of universal hepatitis C virus testing for Middle-Aged adults who inject drugs. Am J Prev Med. 2023;64(1):96\u2013104.","journal-title":"Am J Prev Med"},{"issue":"1","key":"727_CR35","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jamainternmed.2015.6011","volume":"176","author":"HS Chahal","year":"2016","unstructured":"Chahal HS, Marseille EA, Tice JA, Pearson SD, Ollendorf DA, Fox RK, et al. Cost-effectiveness of early treatment of hepatitis C virus genotype 1 by stage of liver fibrosis in a US treatment-Naive population. JAMA Intern Med. 2016;176(1):65\u201373.","journal-title":"JAMA Intern Med"},{"key":"727_CR36","doi-asserted-by":"crossref","unstructured":"Chidi AP, Bryce CL, Donohue JM, Fine MJ, Landsittel DP, Myaskovsky L et al. Economic and public health impacts of policies restricting access to hepatitis C treatment for Medicaid patients. Value Health. 2016;19(4):326\u201334.","DOI":"10.1016\/j.jval.2016.01.010"},{"issue":"1","key":"727_CR37","doi-asserted-by":"publisher","first-page":"ofy353","DOI":"10.1093\/ofid\/ofy353","volume":"6","author":"HS Chahal","year":"2019","unstructured":"Chahal HS, Peters MG, Harris AM, McCabe D, Volberding P, Kahn JG. Cost-effectiveness of hepatitis B virus infection screening and treatment or vaccination in 6 High-risk populations in the united States. Open Forum Infect Dis. 2019;6(1):ofy353.","journal-title":"Open Forum Infect Dis"},{"key":"727_CR38","doi-asserted-by":"crossref","unstructured":"Liu S, Cipriano LE, Holodniy M, Goldhaber-Fiebert JD. Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. Villa E, editor. PLoS ONE. 2013;8(3):e58975.","DOI":"10.1371\/journal.pone.0058975"},{"issue":"1","key":"727_CR39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/hep.26304","volume":"58","author":"P McEwan","year":"2013","unstructured":"McEwan P, Ward T, Yuan Y, Kim R, L\u2019Italien G. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the united States. Hepatology. 2013;58(1):54\u201364.","journal-title":"Hepatology"},{"issue":"3","key":"727_CR40","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/j.1572-0241.2005.40976.x","volume":"100","author":"HH Thein","year":"2005","unstructured":"Thein HH, Krahn M, Kaldor JM, Dore GJ. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol. 2005;100(3):643\u201351.","journal-title":"Am J Gastroenterol"},{"key":"727_CR41","doi-asserted-by":"crossref","unstructured":"Grieve R, Roberts J, Wright M, Sweeting M, DeAngelis D, Rosenberg W, et al. Cost effectiveness of interferon \u03b1 or peginterferon \u03b1 with ribavirin for histologically mild chronic hepatitis C. Gut. 2006;55(9):1332\u20138.","DOI":"10.1136\/gut.2005.064774"},{"issue":"4","key":"727_CR42","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/0272989X06290495","volume":"26","author":"PW Sullivan","year":"2006","unstructured":"Sullivan PW, Ghushchyan V, Preference-Based. EQ-5D index scores for chronic conditions in the united States. Med Decis Mak Int J Soc Med Decis Mak. 2006;26(4):410\u201320.","journal-title":"Med Decis Mak Int J Soc Med Decis Mak"},{"issue":"2","key":"727_CR43","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1572-0241.2001.03537.x","volume":"96","author":"ZM Younossi","year":"2001","unstructured":"Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G. Assessment of utilities and Health-Related quality of life in patients with chronic liver disease. Off J Am Coll Gastroenterol ACG. 2001;96(2):579.","journal-title":"Off J Am Coll Gastroenterol ACG"},{"issue":"3","key":"727_CR44","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1524-4733.2007.00297.x","volume":"11","author":"AR Levy","year":"2008","unstructured":"Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2008;11(3):527\u201338.","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"issue":"3","key":"727_CR45","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/j.1572-0241.2003.07332.x","volume":"98","author":"CAKY Chong","year":"2003","unstructured":"Chong CAKY, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol. 2003;98(3):630\u20138.","journal-title":"Am J Gastroenterol"},{"key":"727_CR46","doi-asserted-by":"crossref","unstructured":"Woo G, Tomlinson G, Yim C, Lilly L, Therapondos G, Wong DK, Ungar WJ, Einarson TR, Sherman M, Heathcote JE. Health state utilities and quality of life in patients with hepatitis B. Can J Gastroenterol Hepatol. 2012 Jul;26(7):445\u2013451.","DOI":"10.1155\/2012\/736452"},{"issue":"3","key":"727_CR47","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1023\/B:DDAS.0000020502.46886.c1","volume":"49","author":"CD Wells","year":"2004","unstructured":"Wells CD, Murrill WB, Arguedas MR. Comparison of Health-Related quality of life preferences between physicians and cirrhotic patients: implications for Cost-Utility analyses in chronic liver disease. Dig Dis Sci. 2004;49(3):453\u20138.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"727_CR48","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1440-1746.2011.06813.x","volume":"27","author":"PC Hsu","year":"2012","unstructured":"Hsu PC, Federico CA, Krajden M, Yoshida EM, Bremner KE, Anderson FH, et al. Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroenterol Hepatol. 2012;27(1):149\u201357.","journal-title":"J Gastroenterol Hepatol"},{"key":"727_CR49","doi-asserted-by":"crossref","unstructured":"Stepanova M, Nader F, Cure S, Bourhis F, Hunt S, Younossi ZM. Patients\u2019 preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens. Aliment Pharmacol Ther. 2014;40(6):676\u201385.","DOI":"10.1111\/apt.12880"},{"issue":"5","key":"727_CR50","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/hep.510300504","volume":"30","author":"AJ Rodger","year":"1999","unstructured":"Rodger AJ, Jolley D, Thompson SC, Lanigan A, Crofts N. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology. 1999;30(5):1299\u2013301.","journal-title":"Hepatology"},{"issue":"4","key":"727_CR51","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1177\/0272989X08315240","volume":"28","author":"DJ McLernon","year":"2008","unstructured":"McLernon DJ, Dillon J, Donnan PT. Health-state utilities in liver disease: a systematic review. Med Decis Mak Int J Soc Med Decis Mak. 2008;28(4):582\u201392.","journal-title":"Med Decis Mak Int J Soc Med Decis Mak"},{"issue":"3","key":"727_CR52","first-page":"321","volume":"14","author":"AA Dan","year":"2008","unstructured":"Dan AA, Kallman JB, Srivastava R, Younoszai Z, Kim A, Younossi ZM. Impact of chronic liver disease and cirrhosis on health utilities using SF-6D and the health utility index. Liver Transpl Off Publ Am Assoc Study Liver Dis Int Liver Transpl Soc. 2008;14(3):321\u20136.","journal-title":"Liver Transpl Off Publ Am Assoc Study Liver Dis Int Liver Transpl Soc"},{"issue":"4","key":"727_CR53","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.acra.2018.10.007","volume":"26","author":"B Gong","year":"2019","unstructured":"Gong B, Nugent JP, Guest W, Parker W, Chang PJ, Khosa F, et al. Influence of artificial intelligence on Canadian medical students\u2019 preference for radiology specialty: anational survey study. Acad Radiol. 2019;26(4):566\u201377.","journal-title":"Acad Radiol"},{"key":"727_CR54","doi-asserted-by":"crossref","unstructured":"Maddigan SL, Feeny DH, Johnson JA. Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian national population health survey. Qual Life Res. 2005;14(5):1311\u201320.","DOI":"10.1007\/s11136-004-6640-4"},{"issue":"5","key":"727_CR55","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40273-017-0606-1","volume":"36","author":"P Thokala","year":"2018","unstructured":"Thokala P, Ochalek J, Leech AA, Tong T. Cost-Effectiveness thresholds: the Past, the present and the future. PharmacoEconomics. 2018;36(5):509\u201322.","journal-title":"PharmacoEconomics"},{"key":"727_CR56","doi-asserted-by":"crossref","unstructured":"Pichon-Riviere A, Drummond M, Palacios A, Garcia-Marti S, Augustovski F. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. Lancet Glob Health. 2023;11(6):e833\u201342.","DOI":"10.1016\/S2214-109X(23)00162-6"},{"issue":"4","key":"727_CR57","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40121-016-0134-x","volume":"5","author":"R Nu\u00f1o Solin\u00eds","year":"2016","unstructured":"Nu\u00f1o Solin\u00eds R, Arratibel Ugarte P, Rojo A, Sanchez Gonzalez Y. Value of treating all stages of chronic hepatitis C: A comprehensive review of clinical and economic evidence. Infect Dis Ther. 2016;5(4):491\u2013508.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"727_CR58","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/s12889-018-5261-8","volume":"18","author":"CM Wright","year":"2018","unstructured":"Wright CM, Boudar\u00e8ne L, Ha NT, Wu O, Hawkins N. A systematic review of hepatitis B screening economic evaluations in low- and middle-income countries. BMC Public Health. 2018;18(1):373.","journal-title":"BMC Public Health"},{"issue":"1","key":"727_CR59","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10900-019-00699-6","volume":"45","author":"E Ortiz","year":"2020","unstructured":"Ortiz E, Scanlon B, Mullens A, Durham J. Effectiveness of interventions for hepatitis B and C: A systematic review of Vaccination, Screening, health promotion and linkage to care within higher income countries. J Community Health. 2020;45(1):201\u201318.","journal-title":"J Community Health"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-026-00727-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00727-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-026-00727-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T11:03:20Z","timestamp":1774523000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12962-026-00727-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["727"],"URL":"https:\/\/doi.org\/10.1186\/s12962-026-00727-y","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}